Tsang JY[au] - Search Results

Year	Number of Results
1982	1
1986	2
1987	1
1988	1
1990	1
1992	1
1997	1
2000	1
2002	3
2003	1
2004	1
2005	1
2006	3
2007	3
2008	2
2009	3
2010	2
2011	4
2012	10
2013	13
2014	10
2015	12
2016	8
2017	7
2018	9
2019	8
2020	14
2021	10
2022	4

1

Molecular Classification of Breast Cancer.

Tsang JYS, Tse GM. Tsang JYS, et al. Adv Anat Pathol. 2020 Jan;27(1):27-35. doi: 10.1097/PAP.0000000000000232. Adv Anat Pathol. 2020. PMID: 31045583 Review.

2

Tumor Microenvironment in Breast Cancer-Updates on Therapeutic Implications and Pathologic Assessment.

Li JJ, Tsang JY, Tse GM. Li JJ, et al. Among authors: tsang jy. Cancers (Basel). 2021 Aug 23;13(16):4233. doi: 10.3390/cancers13164233. Cancers (Basel). 2021. PMID: 34439387 Free PMC article. Review.

3

Breast cancer with neuroendocrine differentiation: an update based on the latest WHO classification.

Tsang JY, Tse GM. Tsang JY, et al. Mod Pathol. 2021 Jun;34(6):1062-1073. doi: 10.1038/s41379-021-00736-7. Epub 2021 Feb 2. Mod Pathol. 2021. PMID: 33531618 Review.

4

Papillary lesions of the breast: A systematic evaluation of cytologic parameters.

Jamidi SK, Li JJX, Aphivatanasiri C, Chow MBCY, Chan RCK, Ng JKM, Tsang JY, Tse GM. Jamidi SK, et al. Among authors: tsang jy. Cancer Cytopathol. 2021 Aug;129(8):649-661. doi: 10.1002/cncy.22412. Epub 2021 Feb 9. Cancer Cytopathol. 2021. PMID: 33561323

5

SETD2 alterations and histone H3K36 trimethylation in phyllodes tumor of breast.

Tsang JY, Lai ST, Ni YB, Shao Y, Poon IK, Kwan JS, Chow C, Shea KH, Tse GM. Tsang JY, et al. Breast Cancer Res Treat. 2021 Jun;187(2):339-347. doi: 10.1007/s10549-021-06181-z. Epub 2021 Apr 12. Breast Cancer Res Treat. 2021. PMID: 33844099

6

INSM1 is a novel prognostic neuroendocrine marker for luminal B breast cancer.

Razvi H, Tsang JY, Poon IK, Chan SK, Cheung SY, Shea KH, Tse GM. Razvi H, et al. Among authors: tsang jy. Pathology. 2021 Feb;53(2):170-178. doi: 10.1016/j.pathol.2020.07.004. Epub 2020 Sep 17. Pathology. 2021. PMID: 32951906

7

Re: INSM1 is a novel prognostic neuroendocrine marker for luminal B breast cancer: author reply.

Razvi H, Tsang JY, Tse GM. Razvi H, et al. Among authors: tsang jy. Pathology. 2021 Feb;53(2):293-294. doi: 10.1016/j.pathol.2020.12.002. Epub 2020 Dec 28. Pathology. 2021. PMID: 33384156 No abstract available.

8

SALL4 promotes tumor progression in breast cancer by targeting EMT.

Chen T, Tsang JYS, Su XC, Li P, Sun WQ, Wong ILK, Choy KY, Yang Q, Tse GMK, Chan TH, Chow LMC. Chen T, et al. Among authors: tsang jys. Mol Carcinog. 2020 Oct;59(10):1209-1226. doi: 10.1002/mc.23250. Epub 2020 Aug 24. Mol Carcinog. 2020. PMID: 32835442

9

The Clinical Significance of Neuroendocrine Features in Invasive Breast Carcinomas.

Lai BS, Tsang JY, Poon IK, Shao Y, Chan SK, Tam FK, Cheung SY, Shea KH, Tse GM. Lai BS, et al. Among authors: tsang jy. Oncologist. 2020 Sep;25(9):e1318-e1329. doi: 10.1634/theoncologist.2020-0081. Epub 2020 Jun 16. Oncologist. 2020. PMID: 32472950 Free PMC article.

10

Co-expression of HLA-I loci improved prognostication in HER2+ breast cancers.

Tsang JY, Ho CS, Ni YB, Shao Y, Poon IK, Chan SK, Cheung SY, Shea KH, Marabi M, Tse GM. Tsang JY, et al. Cancer Immunol Immunother. 2020 May;69(5):799-811. doi: 10.1007/s00262-020-02512-z. Epub 2020 Feb 13. Cancer Immunol Immunother. 2020. PMID: 32055918

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results